Global Burden and Trends of Testicular Cancer in Adolescents and Young Adults from 1990 to 2021, with Predictions to 2035

Overview

Journal Sci Rep

Specialty Science

Date 2024 Dec 31

PMID 39738403

Authors

Shengjian Yu

Zeying Guo

Zijian Qiu

Liejiong Wang

Xiuxia Chen

Feng Xuan

Affiliations

Soon will be listed here.

Abstract

Testicular cancer predominantly affects adolescents and young adults (AYAs) aged 15-39 years. This study analyzed the global, regional, and national burden of testicular cancer among AYAs (1990 to 2021). Data from the Global Burden of Disease study was used to calculate age-standardized rates of incidence (ASIR), prevalence (ASPR), and disability-adjusted life years (ASDR). Trends were assessed using the Joinpoint regression and Bayesian age-period-cohort models, with projections up to 2035. Results showed the global ASIR of 4.05 (95% CI: 3.80-4.35), ASPR of 31.05 (95% CI: 28.88-33.68), and ASDR of 24.82 (95% CI: 22.99-26.91) per 100,000 in 2021, respectively. From 1990 to 2021, ASIR and ASPR increased, while ASDR remained relatively stable. Significant geographical disparities were observed, with Europe and Latin America showing higher burdens compared to Asia and Africa. The 25-29 age group had the highest age-specific rate of incidence (5.58; 95% UI: 5.25-5.97) and disability-adjusted life years (34.09; 95% UI: 31.55-37.11) per 100,000, while the 30-34 age group had the highest age-specific prevalence rate (43.12; 95% UI: 40.51-46.56) per 100,000 in 2021. By 2035, the global numbers of incidence and prevalence cases were projected to increase, with DALYs and age-standardized rates declining. These findings are crucial for informing global strategies in testicular cancer prevention.

References

Le Cornet C, Lortet-Tieulent J, Forman D, Beranger R, Flechon A, Fervers B . Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data. Eur J Cancer. 2013; 50(4):831-9. DOI: 10.1016/j.ejca.2013.11.035. View

. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2100-2132. PMC: 11126520. DOI: 10.1016/S0140-6736(24)00367-2. View

Aareleid T, Sant M, Hedelin G . Improved survival for patients with testicular cancer in Europe since 1978. EUROCARE Working Group. Eur J Cancer. 1999; 34(14 Spec No):2236-40. DOI: 10.1016/s0959-8049(98)00313-x. View

Chertack N, Ghandour R, Singla N, Freifeld Y, Hutchinson R, Courtney K . Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. Cancer. 2020; 126(19):4362-4370. DOI: 10.1002/cncr.33076. View

Das Gupta P . A general method of decomposing a difference between two rates into several components. Demography. 1978; 15(1):99-112. View

Stevens G, Alkema L, Black R, Boerma J, Collins G, Ezzati M . Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016; 388(10062):e19-e23. DOI: 10.1016/S0140-6736(16)30388-9. View

Znaor A, Skakkebaek N, Rajpert-De Meyts E, Laversanne M, Kulis T, Gurney J . Testicular cancer incidence predictions in Europe 2010-2035: A rising burden despite population ageing. Int J Cancer. 2019; 147(3):820-828. PMC: 8612086. DOI: 10.1002/ijc.32810. View

. Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2162-2203. PMC: 11120204. DOI: 10.1016/S0140-6736(24)00933-4. View

. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global.... Lancet. 2024; 403(10440):1989-2056. PMC: 11126395. DOI: 10.1016/S0140-6736(24)00476-8. View

10.

Tverye A, Nangia A, Fantus R . Testicular Cancer Survivorship and Fertility Preservation. Urol Clin North Am. 2024; 51(3):429-438. DOI: 10.1016/j.ucl.2024.03.011. View

11.

Anderson R, Rosenberg H . Age standardization of death rates: implementation of the year 2000 standard. Natl Vital Stat Rep. 1998; 47(3):1-16, 20. View

12.

Xu Y, Xie S, Zhou C, Zhu L, Tong Y, Munoz A . Time trends in the mortality of testicular cancer across the BRICS: an age-period-cohort analysis for the GBD 2019. Sci Rep. 2024; 14(1):12740. PMC: 11148183. DOI: 10.1038/s41598-024-63191-9. View

13.

Cheng L, Albers P, Berney D, Feldman D, Daugaard G, Gilligan T . Testicular cancer. Nat Rev Dis Primers. 2018; 4(1):29. DOI: 10.1038/s41572-018-0029-0. View

14.

Chovanec M, Lauritsen J, Bandak M, Oing C, Kier G, Kreiberg M . Late adverse effects and quality of life in survivors of testicular germ cell tumour. Nat Rev Urol. 2021; 18(4):227-245. DOI: 10.1038/s41585-021-00440-w. View

15.

Tuo Y, Li Y, Li Y, Ma J, Yang X, Wu S . Global, regional, and national burden of thalassemia, 1990-2021: a systematic analysis for the global burden of disease study 2021. EClinicalMedicine. 2024; 72:102619. PMC: 11090906. DOI: 10.1016/j.eclinm.2024.102619. View

16.

Barrios C, Werutsky G, Mohar A, Ferrigno A, Muller B, Bychkovsky B . Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward. Lancet Oncol. 2021; 22(11):e474-e487. DOI: 10.1016/S1470-2045(21)00492-7. View

17.

Mucci L, Hjelmborg J, Harris J, Czene K, Havelick D, Scheike T . Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA. 2016; 315(1):68-76. PMC: 5498110. DOI: 10.1001/jama.2015.17703. View

18.

van Basten J, Hoekstra H, van Driel M, Koops H, Droste J, van de Wiel H . Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy. J Clin Oncol. 1997; 15(6):2442-8. DOI: 10.1200/JCO.1997.15.6.2442. View

19.

Du Z, Chen W, Xia Q, Shi O, Chen Q . Trends and projections of kidney cancer incidence at the global and national levels, 1990-2030: a Bayesian age-period-cohort modeling study. Biomark Res. 2020; 8:16. PMC: 7222434. DOI: 10.1186/s40364-020-00195-3. View

20.

Riebler A, Held L . Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations. Biom J. 2017; 59(3):531-549. DOI: 10.1002/bimj.201500263. View